[Open population comparative randomized clinical trial of lavomax efficacy and safety in combined treatment of non-gonococcal urethritis].
A total of 40 patients with non-gonococcal urethritis (NGU) were divided into two groups. Twenty patients of group 1 received standard antibacterial treatment while 20 patients of group 2 received the same treatment plus an immunotropic drug based on tiloron (lavomax) in a course dose 1.25 g. Patients of group 2 had no recurrences while in group 1 recurrences were seen in 25% patients. Addition of lavomax resulted in clinical and etiological cure and activation of local (secretory IgA) and systemic (interferons alpha and gamma in blood serum) factors in anti-infection defense in NGU patients.
N V
NV
Kungurov
N M
NM
Gerasimova
N I
NI
Skidan
A P
AP
Gorbunov
N P
NP
Evstigneeva
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D016898:Interferon-alpha / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D008297:Male; D008875:Middle Aged; D013994:Tilorone / Q000008:administration & dosage* / Q000009:adverse effects*; D014526:Urethritis / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D007070:Immunoglobulin A; D016898:Interferon-alpha; D007371:Interferon-gamma; D013994:Tilorone